(Total Views: 417)
Posted On: 07/24/2019 6:23:48 PM
Post# of 72445
Every trade today was above yesterday's close.
I'll just say this: every real investor in this stock understands that this deal puts IPIX on a solid footing as it progresses with its pipeline. The bogus claim that "the science is worthless" can now be refuted easily with the simple fact that a major company is putting money and effort into developing this drug.
And make no mistake about it -- having Brilacidin-UP succeed is very important to a privately-held company that knows that its major (and horrendously expensive, in the U.S.) drug is going to face generic competition in a few years.
If Alfasigma can manage to get rights to the entire Brilacidin platform for intestinal diseases, it will make an enormous difference to their company. They NEED Brilacidin-UP to succeed. It's going to be a powerful impetus for them to run with this as quickly as they can.
I'll just say this: every real investor in this stock understands that this deal puts IPIX on a solid footing as it progresses with its pipeline. The bogus claim that "the science is worthless" can now be refuted easily with the simple fact that a major company is putting money and effort into developing this drug.
And make no mistake about it -- having Brilacidin-UP succeed is very important to a privately-held company that knows that its major (and horrendously expensive, in the U.S.) drug is going to face generic competition in a few years.
If Alfasigma can manage to get rights to the entire Brilacidin platform for intestinal diseases, it will make an enormous difference to their company. They NEED Brilacidin-UP to succeed. It's going to be a powerful impetus for them to run with this as quickly as they can.
(3)
(0)
